LIFE

LIFE

Thermo Fisher Scientific Sets Sights on Millipore Takeover

The Burrill Report submits: Shares of scientific toolmaker Millipore (MIL) shot up 23 percent on February 22 as investors speculated about a possible $6 billion takeover of the company by Thermo Fisher Scientific (TMO). The combination would create a lab supply giant and satisfy Thermo's desire to enlarge its footprint in the life sciences market. Both companies have been largely mum regarding a potential tie-up. But Waltham, Massachusetts-based Millipore finally allowed that it had retained Goldman Sachs to explore a possible merger or sale of the company. Despite official refusals to comment on the deal, sources familiar with the talks have told Bloomberg news that Thermo is so eager to acquire Millipore that it has raised its offer for the company. A deal between the two could close as early as next week, the sources say. Millipore's board did not set a timeframe for wrapping up its considerations and says it doesn't plan to say more until it has approved a specific transaction. Thermo, based in Billerica, Massachusetts, went on a $650 million spending spree during fiscal 2009, acquiring seven companies, including BioAnaLab, a U.K. company specializing in the analysis of biologic drugs and vaccines. That trend has continued in 2010, with Fisher picking up handheld spectroscope-maker Ahura Scientific and Finnzymes, a Finnish provider of high performance PCR solutions. “When you look at our acquisition strategy, the larger things we do are going to be centered towards our analytical technology segment. We see great prospects across specialty diagnostics, analytical instruments, and biosciences," Thermo's CEO Mark Casper told investors on the company's fourth quarter earnings call. For now, Millipore says its board is evaluating it options, including the potential pursuit of competing bids. Danaher (DHR), Life Technologies (LIFE) and General Electric (GE) make up the short list of potential bidders that have surfaced in coverage of the scrum, though analysts have discounted GE's interest.Complete Story »

S&P 500 Stocks Up Since 10/9/07

Hickey and Walters (Bespoke) submit:
As noted earlier, Friday marks the two-year anniversary of the S&P 500's closing peak. As of Thursday's close (10/8), only 57 of the 500 stocks currently in the index are up since then. Needless to say, it has been a lousy two years. Below we highlight the 25 best performing stocks in the index over the last two years. As shown, sectors which are the most heavily represented include Technology (7), Energy (6), Consumer Discretionary (5), and Health Care (5). Check back Friday morning for a list of the top performing Mid and Small Cap stocks since 10/9/07.click to enlargeComplete Story »

100% Gainers and Their Estimated P/Es

Hickey and Walters (Bespoke) submit:
The average year to date change of stocks in the S&P 500 is 33.27%, even though the index itself is up just 16.54% YTD. The average estimated P/E ratio for next year for stocks that actually have earnings in the index is 19.47. Twenty-six stocks in the S&P 500 are expected to lose money over the next year. Below we provide a list of S&P 500 stocks that are up more than 100% year to date along with their estimated P/E ratios. As shown, there is a pretty wide variation in valuations of the best performing stocks year to date, with some having low P/Es and some having high or negative P/Es. Micron (MU), Advanced Micro (AMD), Sun Micro (JAVA), Sprint (S), and Office Depot (ODP) are the five stocks up more than 100% in 2009 with negative estimated P/Es. Other strong performing stocks with high valuations include THC, F, SNDK, MOT, and MWV. XL Capital has the lowest P/E estimate of the stocks listed below at 7.40. It is up 370% year to date. Genworth (GNW) is up 325% with a P/E estimate of 11.06, and WDC is up 218% with a P/E estimate of 9.76. Other stocks on the list with a ratio below 20 include FCX, GT, EXPE, WYN, MEE, JWN, GS, CTSH, and LIFE. Complete Story »

A High-Ranked Momentum Stock Portfolio

Scott's Investments submits:Since we have already examined in previous posts the potential for momentum strategies either using moving averages, 52 week or all-time highs (for more posts on those strategies click here or here), or returns over the past year, I thought the readership of the Scott's Investments blog may prefer a twist. I have partnered with Zacks Investment Research to start providing some additional screens to my readers. So, using the stock screener in Zacks Premium service, I've screened for stocks trading within 5% of their 52 week high (in other words, strong momentum) and also having positive earnings surprises the past two quarters, and also having the highest rating from Zacks, a 1. (Zacks ranks stocks on a scale of 1-5, with 1 being a 'strong buy' and 5 being 'strong sell'; the Zacks #1 Rank List has generated an annual average return of 27% since 1988.) One idea I had was to only purchase the top rated stocks if the underlying index (S&P 500) was trading above a long term moving average such as the 200 day moving average. This could potentially reduce some upside gains, but could also reduce drawdowns, such as happened in 2008.Complete Story »

Tech Stocks Rally

Hickey and Walters (Bespoke) submit:
Is it 2003 all over again? Don't look now, but the tech-heavy Nasdaq 100 index is up 25.53% year to date. And both Google (GOOG) and IBM reported stronger than expected earnings after the close tonight, although GOOG is currently trading down while IBM is up. As shown in the chart below, the index just took out its early June highs today after trading up sharply all week long. Looking at individual stocks in the index, Seagate Technology (STX) is up the most in 2009 with a gain of 147.18%, and it's followed closely by Baidu (BIDU) at 146.96%. Sun Micro (JAVA) is up 140%, followed by EXPE (102.91%), MRVL (96.85%), and LINTA (88.46%). The blue-chip tech names have seen huge gains this year as well. Research in Motion (RIMM) is up 78%, Apple (AAPL) is up 73%, Amazon.com (AMZN) is up 67%, and Google is up 43.7%.Complete Story »

Healthcare: Branded Pharma Out, Diagnostics/Generics In

Ryan Barnes submits:When you lose, Don’t lose the lesson - The Dalai Lama For the better part of 5 months I’ve been kicking myself over not dumping Pfizer (PFE) from the Secular Trends Portfolio the day they announced the Wyeth merger. The second I heard about the deal I honestly thought the TV announcer had made a mistake; “No no, it couldn’t be Wyeth. That would just be stupid”Complete Story »

Syndicate content